Neratinib

證據等級: L5

預測適應症: 4 個

Neratinib: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Neratinib is an irreversible pan-HER (HER1/HER2/HER4) tyrosine kinase inhibitor originally developed for HER2-positive breast cancer. The TxGNN model predicts it may also be effective for progesterone-receptor positive breast cancer, with 5 clinical trials and 9 publications currently supporting this direction — though most of this evidence comes from overlapping HER2-positive/HR-positive populations rather than a distinctly defined PR-positive cohort.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer (per known drug class; not captured in this evidence pack — see Germany market status below)
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.68%
Evidence Level	L3
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

A structured MOA field was not available in this evidence pack (data gap DG002). However, literature evidence included in this pack (ExteNET trial, PMID 26874901) describes neratinib as an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, originally used to reduce recurrence risk in HER2-positive breast cancer following trastuzumab-based adjuvant therapy.

Progesterone-receptor (PR) status and HER2 status are not mutually exclusive in breast cancer — many patients are HR-positive (ER and/or PR-positive) and HER2-positive simultaneously. Several of the retrieved trials directly enroll this overlapping population, for example NCT04886531 ("ER-Positive, HER-2 Positive Cancers") and NCT04901299 ("HR-Positive, HER2-Negative Metastatic Breast Cancer"). This suggests the TxGNN model is likely detecting a real biological relationship — neratinib's HER-pathway blockade combined with endocrine therapy in hormone-receptor-driven, HER2-altered tumors — rather than an entirely novel mechanism.

That said, none of the identified trials or publications specifically define "progesterone-receptor positive breast cancer" as an isolated primary endpoint independent of HER2 status. The prediction should therefore be interpreted as an extension within an already-related disease space (breast cancer, HER-pathway biology) rather than a genuinely new therapeutic area.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06131424	N/A	Completed	1151	Retrospective multicenter study on HER2-low prevalence, treatment patterns and outcomes in HER2-negative metastatic breast cancer
NCT04886531	Phase 2	Recruiting	30	Pre-operative neratinib + endocrine therapy + trastuzumab in ER-positive, HER2-positive breast cancer
NCT04901299	Phase 2	Withdrawn	0	Neratinib + fulvestrant in previously treated HR-positive, HER2-negative metastatic breast cancer
NCT05599334	N/A	Completed	111	Retrospective observational study of neratinib as extended adjuvant therapy in early-stage HER2+ breast cancer (European EAP)
NCT04460430	Phase 2	Terminated	12	Neratinib targeting EGFR/ERBB2 in HR-positive/HER2-negative, HER2-enriched advanced/metastatic breast cancer

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26874901	2016	Phase 3 RCT	Lancet Oncology	ExteNET trial: neratinib after trastuzumab-based adjuvant therapy reduces recurrence in early-stage HER2+ breast cancer
27406346	2016	Adaptive Phase 2 Trial	NEJM	I-SPY 2 trial: neratinib added to neoadjuvant chemotherapy in high-risk stage II/III breast cancer
35640077	2022	Guideline	J Clin Oncol	ASCO guideline update on systemic therapy for advanced HER2-positive breast cancer
29784737	2018	Guideline	JNCCN	NCCN Breast Cancer guideline update, covering HER2/endocrine treatment sequencing
39153126	2024	Observational	Breast Cancer Res Treat	Real-world adjuvant neratinib use in HR+/HER2+ early-stage breast cancer; GI toxicity limits continuation
32139271	2020	Expert Roundtable/Review	Clin Breast Cancer	Practice guidance on HER2-positive breast cancer, including neratinib and lapatinib
33726508	2021	Review	Future Oncology	Current treatment trends in HR+/HER2+ breast cancer
32782013	2020	Retrospective In Silico Analysis	Breast Cancer Res	ERBB2 mutation status as prognostic marker in ER+, ERBB2 non-amplified lobular breast carcinoma
35251981	2022	Case Report	Frontiers in Oncology	HER2+ breast cancer with leptomeningeal disease treated with pyrotinib + metronomic vinorelbine
24892840	2013	Review	Clin Adv Hematol Oncol	Overview of metastatic breast cancer subtypes and treatment integration

Germany Market Information

Neratinib currently holds no marketing authorization in Germany (market status: not marketed; 0 authorizations on record). No product-level dosage form or approved indication text is available for this market.

Cytotoxicity

Neratinib is an antineoplastic agent (pan-HER tyrosine kinase inhibitor used in breast cancer), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (irreversible pan-HER1/HER2/HER4 tyrosine kinase inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Not reported as a primary toxicity in the retrieved evidence; per PMID 39153126, the main dose-limiting toxicity in real-world adjuvant use is significant gastrointestinal (diarrhea) rather than hematologic
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	GI symptom monitoring (diarrhea, often requiring prophylaxis/dose reduction per PMID 39153126); liver function; other parameters per package insert
Handling Protection	Please refer to institutional guidelines for handling oral antineoplastic/targeted agents

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Efficacy evidence is biologically plausible and moderately substantial — it draws on overlapping HER2-positive/HR-positive breast cancer trial populations, including a completed Phase 3 RCT (ExteNET) — but it does not directly address "progesterone-receptor positive breast cancer" as a distinct indication. More critically, TFDA/BfArM safety labeling data is a Blocking data gap (DG001), which prevents this candidate from entering the S1 safety pre-assessment stage regardless of efficacy evidence strength.

To proceed, the following is needed:

TFDA/BfArM package insert (warnings, contraindications, DDI) to unblock S1 safety review
Confirmed structured MOA data from DrugBank (DG002)
Clarification of whether "progesterone-receptor positive breast cancer" should be treated as a distinct indication or merged with the existing HER2-positive breast cancer evidence base, given substantial population overlap in the cited trials
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.